【结 构 式】 |
【分子编号】25079 【品名】(1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10-trien-14-one; Naltrexone 【CA登记号】16590-41-3 |
【 分 子 式 】C20H23NO4 【 分 子 量 】341.40696 【元素组成】C 70.36% H 6.79% N 4.1% O 18.75% |
合成路线1
该中间体在本合成路线中的序号:(I)By a Wittig reaction at naltrexone (I) with triphenylmethylphosphonium bromide (II) in DMSO by means of NaH as base.
【1】 Hahn, E.F.; Fishman, J.; Narcotic antagonists. 4. Carbon-6 derivatives of N-substituted noroxymorphones as narcotic antagonists. J Med Chem 1975, 18, 3, 259-262. |
【2】 Hermann, E.C.; Lee, K.T.; Myers, M.J. (DuPont Pharmaceuticals Co.); 17-Substituted-6-desoxy-7,8-dihydro-6alpha-methylnoroxymorphone narcotic antagonists. EP 0039066; JP 167687; US 4322426 . |
【3】 Serradell, M.N.; Castaner, J.; Nalmefene. Drugs Fut 1984, 9, 7, 518. |
合成路线2
该中间体在本合成路线中的序号:(I)The reductocondensation of naltrexone (I) with N-methylbenzylamine (II) by means of sodium cyanoborohydride in THF gives the N-benzyl-N-methylaminomorphinan derivative (III), which is debenzylated by hydrogenation with H2 over Pd/C in methanol yielding the methylaminomorphinan (IV). Finally, this compound is acylated with 3(E)-(3-furyl)acryloyl chloride and NaOH, Na2CO3 or triethylamine in methanol, THF or chloroform. Alternatively, methylaminomorphinan (IV) can also be obtained by direct reductocondensation of naltrexone (I) with methylamine by means of H2 over PtO2 in methanol.
【1】 Leeson, P.A.; Sorbera, L.A.; Castañer, J.; Nalfurafine Hydrochloride. Drugs Fut 2003, 28, 3, 237. |
【2】 Nagase, H.; et al.; Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan. Chem Pharm Bull 1998, 46, 2, 366. |
【3】 Nagase, H.; Hayakawa, J.; Kawamura, H.; Kawai, K.; Endoh, T. (Toray Industries, Inc.); Morphinan derivative and medicinal use. AU 686203; AU 7237394; EP 0663401 . |
【4】 Nagase, H.; Kawai, K.; Endo, T.; Ueno, S.; Negishi, Y. (Toray Industries, Inc.); Antitussive. EP 0657163; JP 1995503397; US 5739145; WO 9501178 . |
【5】 Nagase, H.; Kawai, K.; Kawamura, K.; Hayakawa, J.; Endo, T. (Toray Industries, Inc.); Morphinan deriv. and medicinal use. EP 0577847; EP 0846694; JP 1994509616; US 6277859; US 6323212; WO 9315081 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
11021 | Methanamine; Methylamine | 74-89-5 | CH5N | 详情 | 详情 | |
(I) | 25079 | (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10-trien-14-one; Naltrexone | 16590-41-3 | C20H23NO4 | 详情 | 详情 |
(II) | 11969 | N-Methyl(phenyl)methanamine; N-Benzyl-N-methylamine; N-Methylbenzylamine | 103-67-3 | C8H11N | 详情 | 详情 |
(III) | 25080 | (1S,5R,13R,14R,17S)-14-[benzyl(methyl)amino]-4-(cyclopropylmethyl)-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10-triene-10,17-diol | C28H34N2O3 | 详情 | 详情 | |
(IV) | 25081 | (1S,5R,13R,14R,17S)-4-(cyclopropylmethyl)-14-(methylamino)-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10-triene-10,17-diol | C21H28N2O3 | 详情 | 详情 | |
(V) | 25082 | (E)-3-(3-furyl)-2-propenoyl chloride | C7H5ClO2 | 详情 | 详情 |
合成路线3
该中间体在本合成路线中的序号:(V)Synthesis of [18F]FEtNTI: The intermediate 2-(N1-phenylhydrazino)acetic acid ethyl ester (II) has been obtained by two different ways: 1.- By nitrosation of N-phenylglycine ethyl ester (I) with NaNO2 followed by readuction with Zn/acetic acid (low yields). 2.- By condensation of phenylhydrazine (III) with ethyl bromoacetate (IV) by means of an excess of triethylamine. The cyclization of intermediate (II) with naltrexone (V) by mans of HCl in methanol gives the indolomorphinanylacetic ester (VI), which is benzyl protected at the OH group by means of benzyl bromide and K2CO3 in DMF yielding the benzyl ether (VII). The reduction of the ester group of (VII) with LiAlH4 in THF/toluene afords the indolomorphinanylethanol (VIII), which is treated with tosyl chloride and potassium trimethylsilanolate in toluene to provide the corresponding tosylate (IX). The reaction of (IX) with potassium [18F]fluoride, K2CO3 and Kryptpfix [2.2.2] in hot DMF gives the 18F labeled intermediate (X), which is finally debenzylated by hydrogenation with H2 over Pd/C in DMF/triethylamine.
【1】 Mathews, W.B.; et al.; Synthesis of N1´-([F-18]fluoroethyl)naltrindole ([F-18]FEtNTI): A radioligand for positron emission tomographic studies of delta opioid receptors. J Label Compd Radiopharm 1999, 42, 1, 43. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 25701 | ethyl 2-anilinoacetate | 2216-92-4 | C10H13NO2 | 详情 | 详情 |
(II) | 25702 | ethyl 2-(1-phenylhydrazino)acetate | C10H14N2O2 | 详情 | 详情 | |
(III) | 11818 | Phenyl hydrazine; 1-Phenylhydrazine | 100-63-0 | C6H8N2 | 详情 | 详情 |
(IV) | 16640 | Ethyl 2-bromoacetate; Ethyl bromoacetate | 105-36-2 | C4H7BrO2 | 详情 | 详情 |
(V) | 25079 | (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10-trien-14-one; Naltrexone | 16590-41-3 | C20H23NO4 | 详情 | 详情 |
(VI) | 25704 | ethyl 2-[(1S,2S,13S,21R)-22-(cyclopropylmethyl)-2,16-dihydroxy-14-oxa-22-azaheptacyclo[13.9.1.0(1,13).0(2,21).0(4,12).0(5,10).0(19,25)]pentacosa-4(12),5,7,9,15(25),16,18-heptaen-11-yl]acetate | C31H33NO5 | 详情 | 详情 | |
(VII) | 25705 | ethyl 2-[(1S,2S,13S,21R)-16-(benzyloxy)-22-(cyclopropylmethyl)-2-hydroxy-14-oxa-22-azaheptacyclo[13.9.1.0(1,13).0(2,21).0(4,12).0(5,10).0(19,25)]pentacosa-4(12),5,7,9,15(25),16,18-heptaen-11-yl]acetate | C38H39NO5 | 详情 | 详情 | |
(VIII) | 25706 | (1S,2S,13S,21R)-16-(benzyloxy)-22-(cyclopropylmethyl)-11-(2-hydroxyethyl)-14-oxa-22-azaheptacyclo[13.9.1.0(1,13).0(2,21).0(4,12).0(5,10).0(19,25)]pentacosa-4(12),5,7,9,15(25),16,18-heptaen-2-ol | C36H37NO4 | 详情 | 详情 | |
(IX) | 25707 | 2-[(1S,2S,13S,21R)-16-(benzyloxy)-22-(cyclopropylmethyl)-2-hydroxy-14-oxa-22-azaheptacyclo[13.9.1.0(1,13).0(2,21).0(4,12).0(5,10).0(19,25)]pentacosa-4(12),5,7,9,15(25),16,18-heptaen-11-yl]ethyl 4-methylbenzenesulfonate | C43H43NO6S | 详情 | 详情 | |
(X) | 25708 | (1S,2S,13S,21R)-16-(benzyloxy)-22-(cyclopropylmethyl)-11-(2-fluoroethyl)-14-oxa-22-azaheptacyclo[13.9.1.0(1,13).0(2,21).0(4,12).0(5,10).0(19,25)]pentacosa-4(12),5,7,9,15(25),16,18-heptaen-2-ol | C36H36FNO3 | 详情 | 详情 | |
(X) | 45358 | (1S,2S,13S,21R)-16-(benzyloxy)-22-(cyclopropylmethyl)-11-(2-fluoroethyl)-14-oxa-22-azaheptacyclo[13.9.1.0(1,13).0(2,21).0(4,12).0(5,10).0(19,25)]pentacosa-4(12),5,7,9,15(25),16,18-heptaen-2-ol | C36H36FNO3 | 详情 | 详情 |
合成路线4
该中间体在本合成路线中的序号:(I)Fischer indole cyclization of naltrexone (I) with 4-nitrophenylhydrazine (II) provided 5'-nitronaltrindole (III). Subsequent reduction of the nitro group of (III) by means of hydrazine hydrate and Raney Nickel gave the 5'-amino derivative (IV). Mercury-assisted condensation of (IV) with di(tert-butoxy-carbonyl)thiourea (V) afforded the protected guanidine (VI). Finally, the Boc groups of (VI) were cleaved by treatment with trifluoroacetic acid to furnish the title compound.
【1】 Jones, R.M.; Hjorth, S.A.; Schwartz, T.W.; Portoghese, P.S.; Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. J Med Chem 1998, 41, 25, 4911. |
【2】 Sercel, A.D.; Stevens, W.C. Jr.; Ingals, S.; et al.; Naltrindole analogs as potent and selective kappa-opioid receptor antagonists. 218th ACS Natl Meet (Aug 22 1999, New Orleans) 1999, Abst MEDI 267. |
【3】 Stevens, W.C.; Jones, R.M.; Subramanian, G.; Metzger, T.G.; Ferguson, D.M.; Portoghese, P.S.; Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J Med Chem 2000, 43, 14, 2759. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 25079 | (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10-trien-14-one; Naltrexone | 16590-41-3 | C20H23NO4 | 详情 | 详情 |
(II) | 34400 | 1-(4-nitrophenyl)hydrazine; 4-Nitrophenylhydrazine | 100-16-3 | C6H7N3O2 | 详情 | 详情 |
(III) | 34703 | (1S,2S,13R,21R)-22-(cyclopropylmethyl)-7-nitro-14-oxa-11,22-diazaheptacyclo[13.9.1.0(1,13).0(2,21).0(4,12).0(5,10).0(19,25)]pentacosa-4(12),5,7,9,15(25),16,18-heptaene-2,16-diol | C26H25N3O5 | 详情 | 详情 | |
(IV) | 34704 | (1S,2S,13R,21R)-7-amino-22-(cyclopropylmethyl)-14-oxa-11,22-diazaheptacyclo[13.9.1.0(1,13).0(2,21).0(4,12).0(5,10).0(19,25)]pentacosa-4(12),5,7,9,15(25),16,18-heptaene-2,16-diol | C26H27N3O3 | 详情 | 详情 | |
(V) | 21843 | tert-butyl [(tert-butoxycarbonyl)amino]carbothioylcarbamate | 145013-05-4 | C11H20N2O4S | 详情 | 详情 |
(VI) | 34705 | tert-butyl (Z)-[(tert-butoxycarbonyl)amino][[(1S,2S,13R,21R)-22-(cyclopropylmethyl)-2,16-dihydroxy-14-oxa-11,22-diazaheptacyclo[13.9.1.0(1,13).0(2,21).0(4,12).0(5,10).0(19,25)]pentacosa-4(12),5,7,9,15(25),16,18-heptaen-7-yl]amino]methylidenecarbamate | C37H45N5O7 | 详情 | 详情 |
合成路线5
该中间体在本合成路线中的序号:(I)The title compound was prepared by condensation of naltrexone hydrochloride (I) with 2-(4-chlorophenyl)malondialdehyde (II) in the presence of ammonium acetate in refluxing AcOH.
【1】 Ananthan, S.; Kezar, H.S. III; Carter, R.L.; et al.; Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans. J Med Chem 1999, 42, 18, 3527. |
【2】 Ananthan, S. (Southern Research Institute); Pyridomorphinans and use thereof. WO 0112196 . |
合成路线6
该中间体在本合成路线中的序号:(I)The title polycyclic compound was synthesized by Fisher indolization of naltrexone (I) with 1-amino-6-fluoro-1,2,3,4-tetrahydroquinoline (II) in the presence of methanesulfonic acid in refluxing EtOH.
【1】 Maeda, M.; et al.; Rational drug design and synthesis of opioid delta-receptor selective antagonist TRK-851 and its antitussive activity. 20th Symp Med Chem (Dec 6 2000, Tokyo) 2000, Abst 1P-16. |
【2】 Nagase, H.; Kawai, K.; Endo, T.; Ueno, S.; Maeda, M.; Sakami, S. (Toray Industries, Inc.); Indole derivs. and medicinal use thereof. EP 0805157; US 5849731; WO 9711948 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 25079 | (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10-trien-14-one; Naltrexone | 16590-41-3 | C20H23NO4 | 详情 | 详情 |
(II) | 47354 | 6-fluoro-3,4-dihydro-1(2H)-quinolinamine; 6-fluoro-3,4-dihydro-1(2H)-quinolinylamine | C9H11FN2 | 详情 | 详情 |
合成路线7
该中间体在本合成路线中的序号:(I)Condensation of naltrexone (I) with benzylamine produces the intermediate imine (II) which is subsequently cyclized with trans-beta-nitrostyrene (III) to produce the required pyrrolomorphinan.
【1】 Miller, C.N.; Traynor, J.R.; Aceto, M.D.; Husbands, S.M.; Lewis, J.W.; Srivastava, S.K.; 4'-Arylpyrrolomorphinans: Effect of a pyrrolo-N-benzyl substituent in enhancing delta-opioid antagonist activity. J Med Chem 2002, 45, 2, 537. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 25079 | (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10-trien-14-one; Naltrexone | 16590-41-3 | C20H23NO4 | 详情 | 详情 |
(II) | 56967 | (1S,5R,13R,17S)-14-(benzylimino)-4-(cyclopropylmethyl)-12-oxa-4-azapentacyclo[9.6.1.0~1,13~.0~5,17~.0~7,18~]octadeca-7(18),8,10-triene-10,17-diol | C27H30N2O3 | 详情 | 详情 | |
(III) | 56968 | trans-1-Nitro-2-phenylethylene | 5153-67-3 | C8H7NO2 | 详情 | 详情 |
合成路线8
该中间体在本合成路线中的序号:(I)Fischer indole cyclization of naltrexone (I) with 4-(cyanomethyl)phenylhydrazine (II) produces the indolomorphinan derivative (III). Subsequent reduction of the cyano group of (III) by catalytic hydrogenation over Raney-nickel produces amine (IV). This is then condensed with methyl acetimidate (V) to furnish the corresponding amidine.
【1】 Stevens, W.C.; Jones, R.M.; Subramanian, G.; Metzger, T.G.; Ferguson, D.M.; Portoghese, P.S.; Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J Med Chem 2000, 43, 14, 2759. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 25079 | (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10-trien-14-one; Naltrexone | 16590-41-3 | C20H23NO4 | 详情 | 详情 |
(II) | 64330 | 2-(4-hydrazinophenyl)acetonitrile | C8H9N3 | 详情 | 详情 | |
(III) | 64331 | 2-[(1S,2S,13R,21R)-22-(cyclopropylmethyl)-2,16-dihydroxy-14-oxa-11,22-diazaheptacyclo[13.9.1.0~1,13~.0~2,21~.0~4,12~.0~5,10~.0~19,25~]pentacosa-4(12),5,7,9,15(25),16,18-heptaen-7-yl]acetonitrile | C28H27N3O3 | 详情 | 详情 | |
(IV) | 64332 | (1S,2S,13R,21R)-7-(2-aminoethyl)-22-(cyclopropylmethyl)-14-oxa-11,22-diazaheptacyclo[13.9.1.0~1,13~.0~2,21~.0~4,12~.0~5,10~.0~19,25~]pentacosa-4(12),5,7,9,15(25),16,18-heptaene-2,16-diol | C28H31N3O3 | 详情 | 详情 | |
(V) | 54699 | Methyl ethanimidoate; Methyl acetimidate | C3H7NO | 详情 | 详情 |
合成路线9
该中间体在本合成路线中的序号:(I)
【1】 Doshan HD, Perez J. 2006. Synthesis of (R)-N-methylnaltrexone. WO 2006127899. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 25079 | (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10-trien-14-one; Naltrexone | 16590-41-3 | C20H23NO4 | 详情 | 详情 |
(II) | 67283 | (4S,4aR,7aS,12bR)-3-(cyclopropylmethyl)-4a-hydroxy-7-oxo-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl isobutyrate | C24H29NO5 | 详情 | 详情 | |
(III) | 67284 | (4S,4aR,7aS,12bR)-3-(cyclopropylmethyl)-4a-hydroxy-9-(isobutyryloxy)-3-methyl-7-oxo-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium iodide | C25H32INO5 | 详情 | 详情 | |
(IV) | 67282 | (4S,4aR,7aS,12bR)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-7-oxo-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium bromide | C21H27BrNO4 | 详情 | 详情 |